News

Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) ...
Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...
Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...
After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...
The terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid in Japan include an upfront payment, payment related to the 2024/2025 season, annual ...
Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...
FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD- Utah study ...
The news follows comments by HHS Secretary Robert Kennedy Jr. that introduced uncertainty regarding the effectiveness of Novavax’s COVID-19 vaccine, Nuvaxovid. This most recent update indicates that ...
The company noted that the improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid in Japan include an upfront payment, payment ...
The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 ...